Junshi biological terminates its cooperation with AstraZeneca

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

China's Discount Retailer Vipshop Achieves Revenue of CNY 27.5 Bn in Q1 2023, Up 9% YoY

With the recovery of consumer spending, Vipshop is further enriching the supply of branded products to meet the fast-growing demand for quality consumption.

Chinese E-commerce Giant Pinduoduo Achieves Revenue of CNY 37.64 Bn in Q1 2023, Up 58% YoY

Since this year, Pinduoduo has accelerated its strategic transformation from fast to stable, from speed to quality. Currently, Pinduoduo aims to integrate high-quality development across all domains of platform governance, merchant ecology, high-quality supply chain, and high-quality consumption.

Semiconductor Company iSABers materials Completes Over $220 Million Series A++ Financing

iSABers materials (Chinese: 青禾晶元), a semiconductor materials bonding and integration technology company, announced that it has completed a Series A++ financing round totaling RMB 220 million.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.